A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511344-11-00

Acronym

AG120-C-001

Enrollment

Registered

2024-08-14

Start date

2014-07-18

Completion date

Unknown

Last updated

2025-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026